相似文献
1
Drug delivery systems in urology--getting "smarter".
Urology. 2006 Sep;68(3):463-9. doi: 10.1016/j.urology.2006.03.069.
2
Transdermal delivery of drugs for urologic applications: basic principles and applications.
Urology. 2006 Apr;67(4):657-64. doi: 10.1016/j.urology.2005.11.039.
3
The drug-device continuum in the management of urological disease.
BJU Int. 2008 May;101(9):1179-80. doi: 10.1111/j.1464-410X.2008.07652.x.
4
Microelectromechanical systems in drug delivery.
Med Device Technol. 2003 Dec;14(10):21-4.
5
Novel foam drug carrier is developed to treat urinary diseases.
Nanomedicine (Lond). 2013 Mar;8(3):327.
6
The urogynaecologist's perspective.
BJU Int. 2006 Aug;98(2):461-2. doi: 10.1111/j.1464-410X.2006.06412.x.
7
An implantable MEMS drug delivery device for rapid delivery in ambulatory emergency care.
Biomed Microdevices. 2009 Jun;11(3):625-31. doi: 10.1007/s10544-008-9272-6.
8
[Drugs flourishing in urology].
Prog Urol. 2013 Nov;23(15):1199-200. doi: 10.1016/j.purol.2013.09.006. Epub 2013 Oct 22.
9
Micro- and nano-fabricated implantable drug-delivery systems: current state and future perspectives.
Ther Deliv. 2014 Nov;5(11):1167-70. doi: 10.4155/tde.14.90.
10
[Side effects of drug therapy in urology].
Urologe A. 2017 Apr;56(4):449-450. doi: 10.1007/s00120-017-0344-1.
引用本文的文献
1
Insights into the Safety and Versatility of 4D Printed Intravesical Drug Delivery Systems.
Pharmaceutics. 2023 Feb 24;15(3):757. doi: 10.3390/pharmaceutics15030757.
2
Otorhinolaryngological adverse effects of urological drugs.
Int Braz J Urol. 2021 Jul-Aug;47(4):747-752. doi: 10.1590/S1677-5538.IBJU.2021.99.06.
3
Positively charged cyclodextrins as effective molecular transporters of active phosphorylated forms of gemcitabine into cancer cells.
Sci Rep. 2017 Aug 21;7(1):8353. doi: 10.1038/s41598-017-08727-y.
4
Safety and efficacy of Intraurethral Mitomycin C Hydrogel for prevention of post-traumatic anterior urethral stricture recurrence after internal urethrotomy.
J Inj Violence Res. 2016 Jul;8(2):75-9. doi: 10.5249/jivr.v8i2.812. Epub 2016 Apr 19.
5
Advances in intravesical therapy for urinary tract disorders.
Expert Opin Drug Deliv. 2016;13(1):71-84. doi: 10.1517/17425247.2016.1100166. Epub 2015 Oct 19.
6
Selective binding of lectins to normal and neoplastic urothelium in rat and mouse bladder carcinogenesis models.
Protoplasma. 2014 Jan;251(1):49-59. doi: 10.1007/s00709-013-0524-9. Epub 2013 Jul 5.
7
State of the art in intravesical therapy for lower urinary tract symptoms.
Rev Urol. 2010 Fall;12(4):e181-9.
8
Biodegradable intraprostatic doxorubicin implants.
AAPS J. 2007 Jun 29;9(2):E241-50. doi: 10.1208/aapsj0902027.
本文引用的文献
1
An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer.
J Clin Pharmacol. 2005 Nov;45(11):1245-9. doi: 10.1177/0091270005281043.
2
Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.
Urology. 2005 Oct;66(4):726-31. doi: 10.1016/j.urology.2005.04.062.
3
Biodegradable stents with elastic memory.
Biomaterials. 2006 Mar;27(8):1573-8. doi: 10.1016/j.biomaterials.2005.09.002. Epub 2005 Sep 21.
4
In vivo delivery of BCNU from a MEMS device to a tumor model.
J Control Release. 2005 Aug 18;106(1-2):138-45. doi: 10.1016/j.jconrel.2005.04.009.
5
Microfluidic system for studying the interaction of nanoparticles and microparticles with cells.
Anal Chem. 2005 Sep 1;77(17):5453-9. doi: 10.1021/ac050312q.
6
Novel delivery of oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy model.
J Urol. 2005 Sep;174(3):1133-6. doi: 10.1097/01.ju.0000168617.17080.46.
7
Intraprostatic chemotherapy: distribution and transport mechanisms.
Clin Cancer Res. 2005 Jun 1;11(11):4204-11. doi: 10.1158/1078-0432.CCR-04-1969.
8
Parylene flexible neural probes integrated with microfluidic channels.
Lab Chip. 2005 May;5(5):519-23. doi: 10.1039/b417497f. Epub 2005 Apr 12.
9
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
J Clin Oncol. 2005 Jul 20;23(21):4591-601. doi: 10.1200/JCO.2005.05.160. Epub 2005 Apr 18.
10
Cancer nanotechnology: opportunities and challenges.
Nat Rev Cancer. 2005 Mar;5(3):161-71. doi: 10.1038/nrc1566.
Zotero 插件